Second-Generation Anti-epileptics Segment Held Largest Share of Type Segment in Epilepsy Drugs Market

According to our latest study on " Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis – by Treatment, Distribution Channel, and Geography," the epilepsy drugs market size was valued at US$ 7,768.50 million in 2022 and is projected to reach US$ 10,705.48 million by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The report highlights the key factors and trends impacting the epilepsy drugs market growth and focuses on prominent players and their strategies.

Based on treatment, the epilepsy drugs market is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share in epilepsy drugs market; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.
The third-generation AEDs mainly include eslicarbazepine acetate, lacosamide, and Cannabidiol. The drugs are claimed to be superior to previously known first- and second-generation AEDs in terms of safety and efficacy. The majority of new AEDs are used to control focal seizures, as well as in specific epileptic syndromes (Lennox–Gastaut syndrome and Dravet syndrome) and tuberous sclerosis. Third-generation AEDs have fewer adverse side effects, resulting in increased patient treatment adherence. The majority of new AEDs are used to control focal seizures, as well as in specific epileptic syndromes. Most of these third-generation drugs are effective, safe, and generally well-tolerated in children. Third-generation drugs are gaining importance but are not prescribed as frequently as second-generation antiepileptic drugs.

Based on distribution channel, the epilepsy drugs market is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share in epilepsy drugs market; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030.  Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drugs market.
Retail pharmacy stores sell prescription drugs, over-the-counter (OTC) drugs, and some fast-moving consumer goods, along with providing related services. The epilepsy need medication on an ongoing basis, making prescription-based medicines mandatory, which help in the expansion of retail pharmacies. Modern retail pharmacy chains are digitized, organized, and tech-enabled, which allows them to track medication inventories and sell 100% reliable goods. In addition, retail pharmacy chains provide value-added services for consumers having medical claims or insurance filing to be done. They can also be requested to refurbish previous bills or memos.

UCB SA, Novartis AG, Pfizer Inc, GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma company, Teva Pharmaceutical Industries Ltd, Catalyst Pharmaceuticals Inc, and Alkem Laboratories Ltd are among the key players operating in the global epilepsy drugs market.

The report segments the global epilepsy drugs market as follows:

The epilepsy drugs market is segmented based on treatment, distribution channel, and geography. Based on treatment, the market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. Based on distribution channel, the market is classified into hospital pharmacy, retail pharmacy stores, and others. Based on geography, the market is divided into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com